Exchanges: NASDAQ | NYSE | XLON | AMS | ADS | TSE | BRU
Stronger Sell Today LABD ranks #4847 as SELL CANDIDATE #4847 Weaker Sell

LABD stock forecast Direxion Daily S&P Biotech Bear 3X ETF

LABD stock forecast

Wednesday June 19, 2019 Change -0.74% Price $18.75
Chart period: 2019-03-20 - 2019-06-19
VOLUME
Sell
TREND
Hold
MV LONG
Sell

MV SHORT
Sell

PIVOT
Sell

MACD
Sell

Social Sentiment for LABD

Today's data is from 6 opinions on StockTwits provided by IEX Cloud.
Bullish vs. Bearish opinions
50%
50%
Weighted Sentiment -0.23

Will LABD stock price go up or down on Fri, 21 Jun 2019?

Predict

Direxion Daily S&P Biotech Bear 3X ETF Forecast and Stock Analysis

Technical LABD stock analysis for Wednesday June 19, 2019.

Sell candidate since 2019-06-17 Loss -5.54%


Direxion Daily S&P Biotech Bear 3X ETF fell by -0.74% in the last day ( Wednesday, 19th Jun 2019 ) from $18.89 to $18.75 and has now fallen 4 days in a row. During day the stock fluctuated 3.03% from a day low at $18.55 to a day high of $19.11. The price has fallen in 6 of the last 10 days and is down by -16.59% for this period. Volume fell in the last day along with the stock, which is actually a good sign as volume should follow the stock. In the last day the trading volume fell by -1.25 million shares and in total 2.02 million shares bought and sold for approximately $37.80 million.

Quick summary:

  • 30 day high of the LABD stock price was $25.53 and low was $18.46.
  • 90 day high was $25.53 and low was $16.42.
  • 52 week high for the Direxion Daily S&P Biotech Bear 3X ETF - $62.25 and low - $16.42.

Trend

Direxion Daily S&P Biotech Bear 3X ETF has broken the very wide and strong rising short-term trend down. This signalize a slower rising rate, but may also be an early warning about a possible trend shift. Due to trend being broken there will now be resistance at the bottom line of the trend at $20.67. A reaction back to this level may hold a second chance to get out before further falls.

Click here for today's Top 5 Trending Companies

Signals

There are few to none technical positive signals at the moment. Direxion Daily S&P Biotech Bear 3X ETF holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at $21.33 and $22.49. A break-up above any of these levels will issue buy signals. A sales signal was issued from a pivot top point on Friday June 14, 2019, which indicates further falls until a new bottom pivot has been found. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Access today's Top 5 Golden Star Companies

A sell signal from a double bottom formation was found on Tuesday June 11, 2019 with a target of $22.13. Despite the objective of the signal formation has been reached the stock may continue to fall.

Relative Strength Index (RSI)

RSI14 is 33 and the stock is currently not being overbought or oversold

Access full RSI 14 and RSI 21 lists

Support & Resistance

Direxion Daily S&P Biotech Bear 3X ETF finds support from accumulated volume at $18.39.

Support: $18.39 Price: $18.75 Resistance: $20.22

Risk

This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.56 between high and low, or 3.03%. For the last week, the stock has had a daily average volatility of 6.20%.

Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.

6.20 %

Average volatility

Overall risk:

Very Low Low Medium High Very High

Evaluation:

The Direxion Daily S&P Biotech Bear 3X ETF stock holds several negative signals and despite the positive trend we believe Direxion Daily S&P Biotech Bear 3X ETF will perform weak in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. We have upgraded our recommendation for this stock since last evaluation from a Strong Sell Candidate to a Sell Candidate.

Sell Candidate Upgraded
Stronger Sell Today LABD ranks #4847 as SELL CANDIDATE #4847 Weaker Sell

Will LABD stock price go up or down on Fri, 21 Jun 2019?

Predict

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank